Research advances in pharmacogenomics of mercaptopurine.
- Author:
Xiao-Xiao CHEN
1
;
Shu-Hong SHEN
Author Information
1. Department of Hematology and Oncology, Shanghai Children's Medical Center, Medical School of Shanghai Jiaotong University, Shanghai 200127, China. cxxsunny9@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Antimetabolites, Antineoplastic;
therapeutic use;
Humans;
Mercaptopurine;
metabolism;
therapeutic use;
Methyltransferases;
genetics;
Pharmacogenetics;
Polymorphism, Genetic;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
drug therapy;
genetics;
Pyrophosphatases;
genetics
- From:
Chinese Journal of Contemporary Pediatrics
2017;19(9):1027-1033
- CountryChina
- Language:Chinese
-
Abstract:
Mercaptopurine is a common chemotherapeutic drug and immunosuppressive agent and plays an important role in the treatment of acute lymphoblastic leukemia and inflammatory bowel disease. It may cause severe adverse effects such as myelosuppression, which may result in the interruption of treatment or complications including infection or even threaten patients' lives. However, the adverse effects of mercaptopurine show significant racial and individual differences, which reveal the important role of genetic diversity. Recent research advances in pharmacogenomics have gradually revealed the genetic nature of such differences. This article reviews the recent research advances in the pharmacogenomics and individualized application of mercaptopurine.
